Citadel Advisors
TYRA icon

Citadel Advisors’s Tyra Biosciences TYRA Stock Holding History

Citadel Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$590K Buy
+15,396
New +$498K ﹤0.01% 8899
2025
Q4 		– Sell
-111,293
Closed -$2.04M – 14113
2025
Q3 		$1.56M Sell
111,293
-104,843
-49% -$1.2M ﹤0.01% 6582
2025
Q2 		$2.07M Buy
216,136
+119,854
+124% +$1.14M ﹤0.01% 5647
2025
Q1 		$895K Buy
96,282
+40,695
+73% +$527K ﹤0.01% 7209
2024
Q4 		$773K Buy
55,587
+31,635
+132% +$574K ﹤0.01% 7584
2024
Q3 		$563K Buy
+23,952
New +$503K ﹤0.01% 8010
2024
Q2 		– Sell
-16,789
Closed -$275K – 15442
2024
Q1 		$275K Buy
+16,789
New +$275K ﹤0.01% 9647
2023
Q1 		– Sell
-26,717
Closed -$203K – 15536
2022
Q4 		$203K Sell
26,717
-13,902
-34% -$98.3K ﹤0.01% 10108
2022
Q3 		$357K Sell
40,619
-34,226
-46% -$313K ﹤0.01% 9200
2022
Q2 		$535K Sell
74,845
-3,464
-4% -$27.6K ﹤0.01% 8493
2022
Q1 		$838K Sell
78,309
-4
-0% -$47 ﹤0.01% 8117
2021
Q4 		$1.1M Buy
+78,313
New +$1.56M ﹤0.01% 7711

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Citadel Advisors's TYRA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Tyra Biosciences (TYRA) in Q1 2026: 15,396 shares worth $590K. The stake represents ﹤0.01% of the portfolio and ranks #8899 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TYRA as recently as Q3 2025.

Citadel Advisors first reported a position in TYRA in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.07M in Q2 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Citadel Advisors held 15,396 shares of Tyra Biosciences worth $590K as of Q1 2026.
  • Tyra Biosciences was a new Citadel Advisors position in Q1 2026.
  • Tyra Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8899 holding.
  • Citadel Advisors first reported a position in Tyra Biosciences in Q4 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Tyra Biosciences position peaked at $2.07M in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.